公开(公告)号：US20020161035A1

公开(公告)日：2002-10-31

申请号：US09900355

申请日：2001-07-06

Applicant: Photogen, Inc.

Inventor： H. Craig Dees ,  Timothy C. Scott

IPC: A61K039/395 ,  A61K031/352

CPC classification number: A61K41/0057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0071 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/193333

Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

Abstract translation: 描述了新的化学治疗药物和用于治疗人或动物组织中的这种化学治疗药物的某些医疗用途和方法，其中这种药物的主要活性成分是卤化呫吨或卤代呫吨衍生物。 优选地，卤代呫吨是玫瑰红或玫瑰红的功能衍生物。 卤代呫吨构成一系列有用的化学治疗剂，其在某些组织中提供选择性的，持续的积累。 在优选的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官，循环系统 内脏和淋巴系统及相关器官，各种其他组织，如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个优选的实施方案中，这些药物可用于体内或局部给药的各种制剂，包括在液体，半固体，固体或气溶胶输送载体中。

公开(公告)号：US20030133940A1

公开(公告)日：2003-07-17

申请号：US10331735

申请日：2002-12-30

Applicant: Photogen, Inc.

Inventor： H. Craig Dees ,  Timothy C. Scott

IPC: A61K039/395 ,  A61K031/353 ,  A61K048/00

CPC classification number: A61K41/0057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0071 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y02A50/473 ,  Y10T436/193333

Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations useful for intracorporeal or topical administration, including in liquid, semisolid, solid or aerosol delivery vehicles.

公开(公告)号：US20030125376A1

公开(公告)日：2003-07-03

申请号：US10331854

申请日：2002-12-30

Applicant: Photogen, Inc.

Inventor： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

IPC: A61K031/353

CPC classification number: A61K41/0038 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0057 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y10S436/813 ,  Y10S436/819

Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

公开(公告)号：US20010044146A1

公开(公告)日：2001-11-22

申请号：US09803609

申请日：2001-03-09

Applicant: Photogen, Inc.

Inventor： H. Craig Dees ,  John Smolik

IPC: C12N007/01

CPC classification number: C07K14/47 ,  C12N7/00 ,  C12N2760/18451

Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.

公开(公告)号：US20010041354A1

公开(公告)日：2001-11-15

申请号：US09803498

申请日：2001-03-09

Applicant: Photogen, Inc.

Inventor： H. Craig Dees ,  John Smolik

IPC: C12P021/00 ,  C12N015/86

CPC classification number: C07K14/47 ,  C12N7/00 ,  C12N2760/18451

Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.

Abstract translation: 通过应激蛋白和产生的蛋白质产物增强蛋白质生产的控制和稳定来增加病毒，病毒蛋白质和其他相关生物材料的产量的方法。 本发明还涉及用于选择或工程化产生这种增强的稳定化产物的细胞系的方法。 更具体地，本发明的示例性实施方案涉及用于增强病毒剂的产生，显示永久遗传修饰的细胞系的产生，允许的真核细胞系的产生，增强功能重组产物产量以及这些方法的产物的方法。

公开(公告)号：US20020122236A1

公开(公告)日：2002-09-05

申请号：US10045562

申请日：2002-01-10

Applicant: Photogen, Inc.

Inventor： Walter G. Fisher ,  Eric A. Wachter

IPC: G02F001/01 ,  G02F001/23 ,  G02F002/00

CPC classification number: A61K41/008 ,  A61B5/0059 ,  A61B5/0066 ,  A61B5/0068 ,  A61B2017/00053 ,  A61B2017/00057 ,  A61B2017/00243 ,  A61B2017/00867 ,  A61K49/0017 ,  A61M25/0041 ,  A61M25/0133 ,  A61N1/056 ,  A61N5/062 ,  A61N2005/0644 ,  B23K26/0624 ,  B82Y15/00 ,  G01N21/4795

Abstract: Methods and apparatus directed to using modulation to substantially improve detection limits in optical imaging, and to substantially improve the performance of various optical imaging systems. In an illustrative embodiment, such modulation is achieved using a modulated light source, a modulation frequency reference, a detector, and a demodulator. The modulated light source may comprise a light source emitting an inherently modulated output: alternately, this modulated light source may comprise a separate optical modulator and a continuous wave, modulated, or pulsed light source configured so as to impose a modulation in the output of light source. Methods for imaging using such modulation are also disclosed.

Abstract translation: 涉及使用调制以显着改善光学成像中检测限的方法和装置，并且基本上提高各种光学成像系统的性能。 在说明性实施例中，使用调制光源，调制频率参考，检测器和解调器来实现这种调制。 调制光源可以包括发射固有调制输出的光源：交替地，该调制光源可以包括单独的光调制器和被配置为在光输出中施加调制的连续波，调制或脉冲光源 资源。 还公开了使用这种调制进行成像的方法。

公开(公告)号：US20020107281A1

公开(公告)日：2002-08-08

申请号：US09952448

申请日：2001-09-14

Applicant: Photogen, Inc.

Inventor： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter

IPC: A61K031/352

CPC classification number: A61K41/0057

Abstract: The present invention is directed to new methods, medicaments and pharmaceutical compositions and agents for improved cancer treatment that lower recurrence of the primary tumor by causing selective, acute destruction of tumor tissue and thereby exposing the immune system to large amounts of substantially non-denatured tumor material over a short period of time. This effectively vaccinates the host against tumor tissue, allowing the host's immune system to attack any residual tumor tissue, and thereby reduces the recurrence rate and metastasis to remote sites. In preferred embodiments, this enhancement is achieved through application of phototherapeutic or chemotherapeutic modalities that are capable of producing such an acute, necrotic effect on treated lesions without completely denaturing tumor antigens.

Abstract translation: 本发明涉及用于改善癌症治疗的新方法，药物和药物组合物和试剂，其通过引起肿瘤组织的选择性，急性破坏并由此使免疫系统暴露于大量基本上非变性的肿瘤而降低原发性肿瘤的复发 材料在短时间内。 这有效地使宿主免疫肿瘤组织，允许宿主的免疫系统攻击任何残留的肿瘤组织，从而降低远端部位的复发率和转移。 在优选的实施方案中，通过应用能够对治疗的病变产生这种急性坏死作用的光疗法或化学治疗方式而不使肿瘤抗原完全变性来实现该增强。

公开(公告)号：US20020033989A1

公开(公告)日：2002-03-21

申请号：US09779808

申请日：2001-02-08

Applicant: Photogen, Inc.

Inventor： Walter G. Fisher ,  Eric A. Wachter

IPC: G02F001/01 ,  G02B026/00

CPC classification number: A61K41/008 ,  A61B5/0059 ,  A61B5/0066 ,  A61B5/0068 ,  A61B2017/00053 ,  A61B2017/00057 ,  A61B2017/00243 ,  A61B2017/00867 ,  A61K49/0017 ,  A61M25/0041 ,  A61M25/0133 ,  A61N1/056 ,  A61N5/062 ,  A61N2005/0644 ,  B23K26/0624 ,  B82Y15/00 ,  G01N21/4795

Abstract: Methods and apparatus directed to using modulation to substantially improve detection limits in optical imaging, and to substantially improve the performance of various optical imaging systems. In an illustrative embodiment, such modulation is achieved using a modulated light source, a modulation frequency reference, a detector, and a demodulator. The modulated light source may comprise a light source emitting an inherently modulated output; alternately, this modulated light source may comprise a separate optical modulator and a continuous wave, modulated, or pulsed light source configured so as to impose a modulation in the output of light source. Methods for imaging using such modulation are also disclosed.

Abstract translation: 涉及使用调制以显着改善光学成像中检测限的方法和装置，并且基本上提高各种光学成像系统的性能。 在说明性实施例中，使用调制光源，调制频率参考，检测器和解调器来实现这种调制。 调制光源可以包括发射固有调制输出的光源; 交替地，该调制光源可以包括单独的光调制器和被配置为在光源的输出中施加调制的连续波，调制或脉冲光源。 还公开了使用这种调制进行成像的方法。

公开(公告)号：US20020001567A1

公开(公告)日：2002-01-03

申请号：US09817448

申请日：2001-03-26

Applicant: Photogen, Inc.

Inventor： H. Craig Dees ,  Timothy C. Scott ,  Eric A. Wachter ,  Walter G. Fisher ,  John Smolik

IPC: A61K031/365 ,  A61K031/352 ,  A61N001/30

CPC classification number: A61K41/0038 ,  A61B2017/00057 ,  A61B2017/22062 ,  A61B2017/22087 ,  A61F7/00 ,  A61K9/0019 ,  A61K31/352 ,  A61K41/0057 ,  A61K41/008 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/6803 ,  A61K49/0041 ,  A61K49/0433 ,  A61N5/0601 ,  A61N5/062 ,  C07D311/82 ,  Y10S436/813 ,  Y10S436/819

Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation. In embodiments of the present invention, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.

Abstract translation: 描述了新的体内放射碘化物药物和用于治疗人或动物组织的这种高能光疗药物的某些医学用途和方法，其中这种药物的主要活性成分是卤代呫吨或卤化呫吨衍生物。 卤化呫吨构成了一种有效的放射增敏剂，其在用电离辐射照射治疗部位时变得光活化。 在本发明的实施方案中，这些药物用于治疗影响皮肤和相关器官，口腔和消化道及相关器官，泌尿生殖道和相关器官，呼吸道及相关器官的各种病症， 循环系统和相关器官，头颈部，内分泌和淋巴系统及相关器官，各种其他组织，例如结缔组织和手术期间暴露的各种组织表面，以及表现出微生物或寄生虫感染的各种组织。 在另一个实施方案中，这些药物是以包括液体，半固体，固体或气溶胶输送载体在内的各种制剂生产的。

公开(公告)号：US20010041361A1

公开(公告)日：2001-11-15

申请号：US09803634

申请日：2001-03-09

Applicant: Photogen, Inc

Inventor： H. Craig Dees ,  John Smolik

IPC: C12N007/01

CPC classification number: C07K14/47 ,  C12N7/00 ,  C12N2760/18451

Abstract: A method for increasing production yield of viruses, viral proteins, and other related biological materials through enhanced control and stabilization of protein production via stress proteins and the resultant protein products. The present invention is also directed to methods for selection or engineering of cell lines yielding such enhanced stabilized products. More specifically, example embodiments of the present invention are directed to methods for enhancing production of a viral agent, production of cell lines exhibiting permanent genetic modification, production of permissive eucaryotic cell lines, enhancing functional recombinant product yield, and the products of such methods.